ATE343573T1 - Epothilonderivate, ihre synthese und verwendung - Google Patents

Epothilonderivate, ihre synthese und verwendung

Info

Publication number: ATE343573T1
Authority: AT; Austria
Prior art keywords: absent; single bond; synthesis; alkyl; double bond
Prior art date: 1998-06-22

Application number

AT99931120T

Other languages

English (en)

Inventor

Kyriacos Costa Nicolaou

Nigel Paul King

Maurice Raymond Finlay

Yun He

Frank Roschangar

Dionisios Vourloumis

Hans Vallberg

Antony Bigot

Original Assignee

Novartis Pharma Gmbh

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

1999-06-21

Publication date

2006-11-15

1999-06-21 Application filed by Novartis Pharma Gmbh, Scripps Research Inst filed Critical Novartis Pharma Gmbh

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE343573T1 publication Critical patent/ATE343573T1/de

Links

230000015572 biosynthetic process Effects 0.000 title abstract 2
150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
238000003786 synthesis reaction Methods 0.000 title abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229930013356 epothilone Natural products 0.000 abstract 1
FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 abstract 1
FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Silicon Polymers (AREA)
Plural Heterocyclic Compounds (AREA)
Lubricants (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99931120T 1998-06-22 1999-06-21 Epothilonderivate, ihre synthese und verwendung ATE343573T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/102,602 US6380394B1 (en)	1996-12-13	1998-06-22	Epothilone analogs

Publications (1)

Publication Number	Publication Date
ATE343573T1 true ATE343573T1 (de)	2006-11-15

Family

ID=22290705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99931120T ATE343573T1 (de)	1998-06-22	1999-06-21	Epothilonderivate, ihre synthese und verwendung

Country Status (27)

Country	Link
US (3)	US6380394B1 (de)
EP (2)	EP1741715A1 (de)
JP (1)	JP4681732B2 (de)
KR (3)	KR100864742B1 (de)
CN (1)	CN1192031C (de)
AT (1)	ATE343573T1 (de)
AU (1)	AU757854B2 (de)
BR (1)	BR9911420A (de)
CA (1)	CA2334342C (de)
CY (1)	CY1105863T1 (de)
CZ (1)	CZ301783B6 (de)
DE (1)	DE69933767T2 (de)
DK (1)	DK1089998T3 (de)
ES (1)	ES2273502T3 (de)
HU (1)	HUP0102711A3 (de)
ID (1)	ID28210A (de)
IL (3)	IL139784A0 (de)
MX (1)	MXPA00012443A (de)
NO (1)	NO328417B1 (de)
NZ (1)	NZ508622A (de)
PL (1)	PL197648B1 (de)
PT (1)	PT1089998E (de)
RU (1)	RU2227142C2 (de)
SK (2)	SK285647B6 (de)
TR (1)	TR200003844T2 (de)
WO (1)	WO1999067252A2 (de)
ZA (1)	ZA200007059B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4183099B2 (ja)	1995-11-17	2008-11-19	ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃおよびｄ、製造法ならびに組成物
ES2312695T3 (es) *	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) *	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) *	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
DE19820599A1 (de) *	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
WO2000031247A2 (en)	1998-11-20	2000-06-02	Kosan Biosciences, Inc.	Recombinant methods and materials for producing epothilone and epothilone derivatives
CZ301498B6 (cs) *	1999-02-22	2010-03-24	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	C-21 modifikované epothilony
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
EP1169038B9 (de)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Cyclische protein-tyrosinkinasehemmer
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
EP1232149A2 (de) *	1999-11-24	2002-08-21	Gesellschaft für biotechnologische Forschung mbH (GBF)	Fungizid wirkende melithiazol-derivate
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
WO2001092255A2 (en) *	2000-05-26	2001-12-06	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
CA2422500A1 (en) *	2000-09-22	2003-03-18	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	Triazolo-epothilones
IL155306A0 (en) *	2000-10-13	2003-11-23	Univ Mississippi	Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
WO2002058699A1 (en) *	2001-01-25	2002-08-01	Bristol-Myers Squibb Company	Pharmaceutical forms of epothilones for oral administration
EE200300323A (et)	2001-01-25	2003-10-15	Bristol-Myers Squibb Company	Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
ES2304240T3 (es)	2001-01-25	2008-10-01	Bristol-Myers Squibb Company	Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
KR20040028720A (ko)	2001-02-20	2004-04-03	브리스톨-마이어스스퀴브컴파니	치료불응성 종양 치료용 에포틸론 유도체
CN1774253A (zh)	2001-02-20	2006-05-17	布里斯托尔-迈尔斯斯奎布公司	用环氧丙酯酮衍生物治疗顽固性肿瘤
NZ527557A (en) *	2001-02-27	2005-05-27	Biotechnolog Forschung Gmbh	Degradation of epothilones and ethynyl substituted epothilones
IL157443A0 (en)	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
MXPA03010909A (es) *	2001-06-01	2004-02-17	Bristol Myers Squibb Co	Derivados de epotilona.
ES2315399T3 (es) *	2001-08-23	2009-04-01	Novartis Ag	Analogos de epotilona ciclobutilo y ciclopropilo.
WO2003026744A1 (en) *	2001-09-25	2003-04-03	Alcon, Inc.	The use of epothilones and analogs in conjunction with ophthalmic surgery
US20050043409A1 (en) *	2001-10-25	2005-02-24	Chen Ying-Nan Pan	Combinations comprising a selective cyclooxygenase-2 inhibitor
AU2002361022A1 (en) *	2001-12-07	2003-06-17	Novartis Ag	Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
MXPA04006822A (es)	2002-01-14	2004-12-08	Novartis Ag	Combinaciones que comprenden epotilonas y anti-metabolitos.
TW200303202A (en) *	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (de) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen
SI1483251T1 (sl) *	2002-03-12	2010-03-31	Bristol Myers Squibb Co	C cian epotilonski derivati
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
TW200403994A (en) *	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
BR0313198A (pt) *	2002-08-02	2005-07-12	Novartis Ag	Derivados de epotilona
US7384964B2 (en) *	2002-08-23	2008-06-10	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP2186811A1 (de) *	2002-08-23	2010-05-19	Sloan-Kettering Institute For Cancer Research	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7649006B2 (en) *	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
GB0221312D0 (en) *	2002-09-13	2002-10-23	Novartis Ag	Organic compounds
AU2003275068B2 (en)	2002-09-23	2009-09-17	Bristol-Myers Squibb Company	Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
SI1553938T1 (sl) *	2002-10-15	2007-06-30	Univ Louisiana State	Uporaba epotilonskih derivatov za zdravljenje hiperparatiroidizma
WO2004045518A2 (en)	2002-11-15	2004-06-03	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (de)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
GB0405898D0 (en) *	2004-03-16	2004-04-21	Novartis Ag	Organic compounds
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
EP1674098A1 (de)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
US7754850B2 (en)	2005-02-11	2010-07-13	University Of Southern California	Chimeric disintegrin domain
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
WO2007015929A2 (en) *	2005-07-27	2007-02-08	University Of Toledo	Epothilone analogues
JP2009516753A (ja) *	2005-11-22	2009-04-23	ザスクリップスリサーチインスティテュート	高度に効力を持つエポチロンの化学合成
US7653731B2 (en) *	2006-02-24	2010-01-26	Microsoft Corporation	Management of connections to external data
EP2029156A4 (de) *	2006-05-01	2010-07-21	Univ Southern California	Kombinationstherapie zur krebsbehandlung
CN101535300B (zh)	2006-05-16	2014-05-28	埃格拉医疗公司	Iap bir域结合化合物
JP2010511408A (ja)	2006-12-04	2010-04-15	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
JP2010518123A (ja)	2007-02-08	2010-05-27	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をキュプレドキシンで予防するための組成物および方法
US8435983B2 (en) *	2007-03-23	2013-05-07	The University Of Toledo	Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (de)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Kombinationen mit einem Prostaglandin und Verwendungen davon
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (de)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Nanopartikel mit modifizierter Oberfläche
CA2729620A1 (en) *	2008-07-03	2010-01-07	Pharma Mar, S.A.	Antitumoral macrolides
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (de)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer
US9284350B2 (en)	2010-02-12	2016-03-15	Pharmascience Inc.	IAP BIR domain binding compounds
US20110300150A1 (en)	2010-05-18	2011-12-08	Scott Eliasof	Compositions and methods for treatment of autoimmune and other disease
JP5889337B2 (ja)	2011-01-20	2016-03-22	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
EP2793947B1 (de)	2011-12-23	2021-02-03	Innate Pharma	Enzymatische konjugation von polypeptiden
US10132799B2 (en)	2012-07-13	2018-11-20	Innate Pharma	Screening of conjugated antibodies
EP3564259A3 (de)	2012-11-09	2020-02-12	Innate Pharma	Kennungen für tgase-vermittelte konjugation
WO2014075391A1 (zh)	2012-11-17	2014-05-22	北京市丰硕维康技术开发有限责任公司	离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014116594A1 (en) *	2013-01-23	2014-07-31	The University Of Toledo	Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10611824B2 (en)	2013-03-15	2020-04-07	Innate Pharma	Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (de)	2013-06-20	2021-04-21	Innate Pharma	Enzymatische konjugation von polypeptiden
CN105517577A (zh)	2013-06-21	2016-04-20	先天制药公司	多肽的酶促偶联
EP3371176A4 (de) *	2015-10-16	2019-09-04	William Marsh Rice University	Epothilon-analoga, syntheseverfahren, behandlungsverfahren und arzneimittelkonjugate dafür
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW221441B (de) *	1991-01-25	1994-03-01	Taiho Pharmaceutical Co Ltd
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
JP4183099B2 (ja)	1995-11-17	2008-11-19	ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃおよびｄ、製造法ならびに組成物
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
ES2312695T3 (es)	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
JP2001513098A (ja)	1997-02-25	2001-08-28	ゲゼルシャフトフュアバイオテクノロギッシェフォーシュンクエムベーハー（ゲーベーエフ）	側鎖を修飾したエポチロン
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
DE19744135C1 (de)	1997-09-29	1999-03-25	Schering Ag	Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

1998
- 1998-06-22 US US09/102,602 patent/US6380394B1/en not_active Expired - Fee Related
1999
- 1999-06-21 EP EP06118853A patent/EP1741715A1/de not_active Ceased
- 1999-06-21 NZ NZ508622A patent/NZ508622A/en not_active IP Right Cessation
- 1999-06-21 CZ CZ20004769A patent/CZ301783B6/cs not_active IP Right Cessation
- 1999-06-21 MX MXPA00012443A patent/MXPA00012443A/es not_active IP Right Cessation
- 1999-06-21 AU AU47748/99A patent/AU757854B2/en not_active Ceased
- 1999-06-21 HU HU0102711A patent/HUP0102711A3/hu unknown
- 1999-06-21 IL IL13978499A patent/IL139784A0/xx unknown
- 1999-06-21 KR KR1020007014546A patent/KR100864742B1/ko not_active Expired - Fee Related
- 1999-06-21 CA CA2334342A patent/CA2334342C/en not_active Expired - Fee Related
- 1999-06-21 CN CNB998077690A patent/CN1192031C/zh not_active Expired - Fee Related
- 1999-06-21 JP JP2000555904A patent/JP4681732B2/ja not_active Expired - Fee Related
- 1999-06-21 AT AT99931120T patent/ATE343573T1/de active
- 1999-06-21 DK DK99931120T patent/DK1089998T3/da active
- 1999-06-21 SK SK1971-2000A patent/SK285647B6/sk not_active IP Right Cessation
- 1999-06-21 TR TR2000/03844T patent/TR200003844T2/xx unknown
- 1999-06-21 ES ES99931120T patent/ES2273502T3/es not_active Expired - Lifetime
- 1999-06-21 SK SK5009-2007A patent/SK287864B6/sk not_active IP Right Cessation
- 1999-06-21 KR KR1020087011102A patent/KR20080045298A/ko not_active Ceased
- 1999-06-21 WO PCT/EP1999/004287 patent/WO1999067252A2/en not_active Ceased
- 1999-06-21 RU RU2000132188/04A patent/RU2227142C2/ru not_active IP Right Cessation
- 1999-06-21 US US09/720,070 patent/US6531497B1/en not_active Expired - Fee Related
- 1999-06-21 EP EP99931120A patent/EP1089998B1/de not_active Expired - Lifetime
- 1999-06-21 ID IDW20002739A patent/ID28210A/id unknown
- 1999-06-21 DE DE69933767T patent/DE69933767T2/de not_active Expired - Lifetime
- 1999-06-21 KR KR1020097010651A patent/KR20090066332A/ko not_active Ceased
- 1999-06-21 PL PL345327A patent/PL197648B1/pl not_active IP Right Cessation
- 1999-06-21 PT PT99931120T patent/PT1089998E/pt unknown
- 1999-06-21 BR BR9911420-8A patent/BR9911420A/pt not_active Application Discontinuation
2000
- 2000-11-20 IL IL139784A patent/IL139784A/en not_active IP Right Cessation
- 2000-11-30 ZA ZA200007059A patent/ZA200007059B/en unknown
- 2000-12-14 NO NO20006378A patent/NO328417B1/no not_active IP Right Cessation
2003
- 2003-03-11 US US10/386,999 patent/US7579366B2/en not_active Expired - Fee Related
2006
- 2006-12-20 CY CY20061101818T patent/CY1105863T1/el unknown
2007
- 2007-04-23 IL IL182744A patent/IL182744A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
ID28210A (id)	2001-05-10
CA2334342C (en)	2012-07-17
HUP0102711A2 (hu)	2001-12-28
MXPA00012443A (es)	2004-12-03
ZA200007059B (en)	2002-01-30
SK19712000A3 (sk)	2001-09-11
SK287864B6 (sk)	2012-02-03
RU2227142C2 (ru)	2004-04-20
HK1038358A1 (en)	2002-03-15
EP1741715A1 (de)	2007-01-10
ES2273502T3 (es)	2007-05-01
NO328417B1 (no)	2010-02-15
PL345327A1 (en)	2001-12-17
SK285647B6 (sk)	2007-05-03
CN1192031C (zh)	2005-03-09
IL139784A0 (en)	2002-02-10
DK1089998T3 (da)	2007-01-15
WO1999067252A3 (en)	2000-03-16
KR100864742B1 (ko)	2008-10-22
DE69933767T2 (de)	2007-09-13
CA2334342A1 (en)	1999-12-29
AU4774899A (en)	2000-01-10
TR200003844T2 (tr)	2001-04-20
CN1306531A (zh)	2001-08-01
NO20006378L (no)	2001-02-21
DE69933767D1 (de)	2006-12-07
US6380394B1 (en)	2002-04-30
EP1089998B1 (de)	2006-10-25
NO20006378D0 (no)	2000-12-14
JP4681732B2 (ja)	2011-05-11
CY1105863T1 (el)	2011-02-02
US20030203938A1 (en)	2003-10-30
NZ508622A (en)	2003-07-25
CZ301783B6 (cs)	2010-06-23
EP1089998A2 (de)	2001-04-11
US7579366B2 (en)	2009-08-25
PT1089998E (pt)	2007-01-31
KR20080045298A (ko)	2008-05-22
KR20010083060A (ko)	2001-08-31
BR9911420A (pt)	2001-03-20
IL139784A (en)	2010-05-17
HUP0102711A3 (en)	2002-09-30
PL197648B1 (pl)	2008-04-30
US6531497B1 (en)	2003-03-11
KR20090066332A (ko)	2009-06-23
IL182744A (en)	2010-05-17
AU757854B2 (en)	2003-03-06
IL182744A0 (en)	2007-07-24
JP2002518504A (ja)	2002-06-25
WO1999067252A2 (en)	1999-12-29
CZ20004769A3 (cs)	2001-07-11

Legal Events

Date

Code

Title

Description

2007-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1089998

Country of ref document: EP

Publication	Publication Date	Title
DE69933767D1 (de)	2006-12-07	Epothilonderivate, ihre synthese und verwendung
LU91210I2 (fr)	2006-11-06	Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
DE69907331D1 (de)	2003-06-05	Fungizide Zusammensetzung enthaltend ein 1,2,3-Thiadiazolderivat sowie deren Verwendung
NL350055I1 (de)	2016-01-18
AU3265595A (en)	1996-03-22	Quinazoline derivative
ATE250573T1 (de)	2003-10-15	Azetidin- und pyrrolidinderivate
DE69111619D1 (de)	1995-08-31	1,4-benzothiazedinderivat.
DE69505968D1 (de)	1998-12-17	Azolidindion-derivate und ihre anwendung als antihyperglykämika
ATE159885T1 (de)	1997-11-15	Fungizide zusammensetzungen
DE69208408D1 (de)	1996-03-28	Phenylthioharnstoffderivate und ihre pharmazeutische Verwendung
FI852223A0 (fi)	1985-06-03	Saosom fungicider anvaenda triazoler.
PL352613A1 (en)	2003-08-25	Derivatives of benzamide, insecticides for agriculture and horticulture as well as their application
NO175253C (no)	1994-09-21	Forbindelse, anvendelse og preparat
NO921282D0 (no)	1992-04-02	Benzotiazolderivater og deres anvendelse
ATE196905T1 (de)	2000-10-15	Thienyl- und furylpyrrol derivate, deren herstellung und deren verwendung als insektizide und akarizide
MX174310B (es)	1994-05-04	Control de microorganismos en plantas con 1-hidroximetilpirazoles